|
Mon, 03/21/2022 - 09:46 |
GT Biopharma Presents TriKE Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting |
Oxis Biotech |
|
Fri, 05/21/2021 - 03:18 |
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX (daratumumab) Subcutaneous Formulation Utilizing ENHANZE |
Halozyme |
|
Mon, 02/22/2021 - 03:20 |
From bedside to bench and back: Researchers reveal a genetic signature that could help overcome drug resistance in some of the most aggressive forms of multiple myeloma |
WeizmannInstitute |
|
Thu, 11/12/2020 - 08:38 |
Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO/ DARZALEX Subcutaneous (SC) Formulation Utilizing ENHANZE Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refr |
Halozyme |
|
Mon, 02/03/2020 - 13:03 |
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma |
GlaxoSmithKline |
|
Mon, 12/16/2019 - 20:48 |
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma |
GlaxoSmithKline |
|
Fri, 12/06/2019 - 16:23 |
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma |
Johnson and Johnson |
|
Wed, 07/03/2019 - 16:04 |
FDA approves new treatment for refractory multiple myeloma |
FDA |
|
Tue, 05/28/2019 - 02:43 |
Expanding the reach of proteasome inhibitors |
Broad Institute |
|
Mon, 12/03/2018 - 02:33 |
ASH 2018 Day 3: Novel Proteasome Inhibitors Update |
MMRF |
|
Sun, 10/14/2018 - 16:54 |
The IMFs 12th Annual Comedy Celebration A Night to Remember |
International M... |
|
Tue, 07/24/2018 - 19:21 |
Building on Research on Immunomodulator Regimens in Relapsed Multiple Myeloma Treatment |
BMS |
|
Thu, 03/02/2017 - 09:06 |
Hello from New Delhi, India! |
MMRF |
|
Wed, 08/17/2016 - 13:26 |
Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX ) |
Johnson and Johnson |
|
Mon, 06/06/2016 - 19:17 |
Moffitt Cancer Center Researchers Present Phase 1 Study Results of Selinexor Combination Therapy for Multiple Myeloma Patients |
Moffitt |
|
Fri, 11/20/2015 - 17:35 |
FDA approves Ninlaro, new oral medication to treat multiple myeloma |
FDA |
|
Mon, 07/06/2015 - 12:48 |
Multiple Myeloma Research Foundation (MMRF) Partners on Daratumumab Expanded Access Program (EAP) Now Open for Multiple Myeloma Patients |
MMRF |
|
Mon, 07/06/2015 - 08:27 |
Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated Multiple Myeloma |
Johnson and Johnson |
